Moderated, page-380

@Beefa9999 thank you for posting. A very comprehensive compilation of information on the company. I agree the board has a very impressive CV, that does engender confidence in their ability to plot the pathways required for approvals, partnerships and growth. So a useful reminder of who is steering the ship.
This report is all about the buy/sell signals of the company information against certain matrices it seems to me. It’s a bit like charts that rightfully have its own thread. However when I was investing in Mesoblast, yes the CEO was important as he was and is the driving force, but the major consideration, and in essence the only consideration was “does it work?”. All these bio tech companies at one stage are at the stage “will it work?”. Mesoblast I knew (Japan) already and that and it’s therapy was safe. I did not know how many areas it would work on. Turns out it seems in one, inflammation. Fortunately, inflammation seems to be a killer in a lot of areas.
That was and still is my buy indicator. Moving on it is all about partnerships/approvals and quality control. None of these can be covered in this sort of report. We are at the black and white stage. Good news we soar. No news we in essence tread water, bad news we collapse. But ultimately, good science = good news, good returns.
Imo Mesoblast is a stock to buy and hold. There are some wonderful analytical posts from much better posters than me, that articulate this on this forum. All that has happened in the past few months is further evidence to support this strategy has also been posted for us to read.
So I/we wait. Next good news cannot be far away.
regards
Yelrom